AU2015276186B2 - 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases - Google Patents

6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases Download PDF

Info

Publication number
AU2015276186B2
AU2015276186B2 AU2015276186A AU2015276186A AU2015276186B2 AU 2015276186 B2 AU2015276186 B2 AU 2015276186B2 AU 2015276186 A AU2015276186 A AU 2015276186A AU 2015276186 A AU2015276186 A AU 2015276186A AU 2015276186 B2 AU2015276186 B2 AU 2015276186B2
Authority
AU
Australia
Prior art keywords
sul
hydroxy
tetramethylchroman
chronic obstructive
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015276186A
Other languages
English (en)
Other versions
AU2015276186A1 (en
Inventor
Gerrit Jan Willem Euverink
Robert Henk Henning
Hermanus Meurs
Martina Schmidt
Adrianus Cornelis Van Der Graaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfateq BV
Original Assignee
Sulfateq BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq BV filed Critical Sulfateq BV
Publication of AU2015276186A1 publication Critical patent/AU2015276186A1/en
Application granted granted Critical
Publication of AU2015276186B2 publication Critical patent/AU2015276186B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015276186A 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases Active AU2015276186B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2013012A NL2013012B1 (en) 2014-06-17 2014-06-17 Compounds for the treatment of chronic obstructive airway diseases.
NL2013012 2014-06-17
PCT/EP2015/063579 WO2015193365A1 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases

Publications (2)

Publication Number Publication Date
AU2015276186A1 AU2015276186A1 (en) 2017-01-12
AU2015276186B2 true AU2015276186B2 (en) 2020-09-10

Family

ID=51358046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015276186A Active AU2015276186B2 (en) 2014-06-17 2015-06-17 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases

Country Status (8)

Country Link
US (3) US9913841B2 (https=)
EP (1) EP3157518B1 (https=)
JP (1) JP6711488B2 (https=)
AU (1) AU2015276186B2 (https=)
CA (1) CA2952288C (https=)
ES (1) ES2784475T3 (https=)
NL (1) NL2013012B1 (https=)
WO (1) WO2015193365A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
EP3672592A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. 6-chromanol derivatives for use as a medicament
ES3013118T3 (en) 2017-08-25 2025-04-11 Sulfateq Bv Medicaments for the treatment of vasoconstriction related diseases or disorders
CA3079483A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
WO2021079300A1 (en) * 2019-10-23 2021-04-29 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59222415A (ja) * 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
EP0202580A2 (en) * 1985-05-13 1986-11-26 Kuraray Co., Ltd. 3,4-Dihydrobenzopyran derivatives
WO1988008424A1 (en) * 1987-04-27 1988-11-03 The Upjohn Company Pharmaceutically active amines
US5290797A (en) * 1991-03-08 1994-03-01 Adir Et Compagnie Benzopyran compounds
US5315017A (en) * 1991-05-03 1994-05-24 Adir Et Compagnie Benzopyran compounds
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
US20040122059A1 (en) * 2002-10-01 2004-06-24 The Penn State Research Foundation PPAR-gamma ligands in the treatment of asthma and allergies
US20050065099A1 (en) * 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2014098586A1 (en) * 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065009A1 (en) 2002-11-05 2005-03-24 Lu Harry H. System and method for making a coiled strip of dunnage
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
EP3142646A1 (en) * 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59222415A (ja) * 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
EP0202580A2 (en) * 1985-05-13 1986-11-26 Kuraray Co., Ltd. 3,4-Dihydrobenzopyran derivatives
WO1988008424A1 (en) * 1987-04-27 1988-11-03 The Upjohn Company Pharmaceutically active amines
US5290797A (en) * 1991-03-08 1994-03-01 Adir Et Compagnie Benzopyran compounds
US5315017A (en) * 1991-05-03 1994-05-24 Adir Et Compagnie Benzopyran compounds
US20040122059A1 (en) * 2002-10-01 2004-06-24 The Penn State Research Foundation PPAR-gamma ligands in the treatment of asthma and allergies
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
US20050065099A1 (en) * 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2014098586A1 (en) * 2012-12-19 2014-06-26 Sulfateq B.V. Compounds for protection of cells

Also Published As

Publication number Publication date
US10322124B2 (en) 2019-06-18
EP3157518A1 (en) 2017-04-26
JP6711488B2 (ja) 2020-06-17
WO2015193365A1 (en) 2015-12-23
CA2952288A1 (en) 2015-12-23
US9913841B2 (en) 2018-03-13
US20170151234A1 (en) 2017-06-01
NL2013012B1 (en) 2016-07-05
ES2784475T3 (es) 2020-09-28
JP2017524674A (ja) 2017-08-31
AU2015276186A1 (en) 2017-01-12
CA2952288C (en) 2024-01-23
US10426771B2 (en) 2019-10-01
US20180250294A1 (en) 2018-09-06
EP3157518B1 (en) 2020-01-15
US20180280384A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
US10426771B2 (en) 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
JP2021004256A (ja) 新規モノチオール粘液溶解剤
MX2014001551A (es) Inhibicion de canal ionico del potencial receptor transitorio a1 (trpa1).
CN112791079A (zh) 贝壳杉烷类化合物在制备治疗勃起功能障碍的药物应用
WO2021230340A1 (ja) 新規吸入剤
JP2014511897A (ja) Ｃｎｓ障害の治療におけるジベンゾチアゼピン誘導体およびその使用
EP1634606A1 (en) Drug for airway administration
CZ285481B6 (cs) 6-(2-imidazolinylamino)chinolinové sloučeniny použitelné jako alfa-2-adrenoceptorové agonisté
NO166282B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt kalsium-9-etyl-6,9-dihydro-4,6-diokso-10-propyl-4h-(3,2-g)-kinolin-2,8-di-karboksylat.
CN115974832A (zh) 一种含有二硫键的n-乙酰- l-半胱氨酸衍生物及其制备方法与应用
US9539248B2 (en) Agent for ameliorating chronic obstructive pulmonary disease
JP2021515811A (ja) ３”，５”−ジアルコシベンゾイル−３’−アミノ−３’−デオキシアデノシン−５’−三リン酸及びその医薬用途
JP6602297B2 (ja) ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
JPS5810577A (ja) ２−セノイルメルカプトプロピオニルグリシンのエステル、その製造法およびそれを有効成分とする医薬組成物
EP4565577A1 (en) Inhibitors and uses therefor
CN116162128A (zh) 一种抗病毒感染的核苷衍生物及其制备方法与用途
CN117562915A (zh) 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
CN103288670B (zh) 多羟基二苯甲酮衍生物及其应用
JP2021536467A (ja) 喘息またはパーキンソン病の処置のための方法および組成物
HK40101641B (zh) 一种抗流感病毒衍生物及其用途
JPWO2004112791A1 (ja) 肺疾患の治療および／または予防剤
JPWO2004087147A1 (ja) 肺疾患の治療および／または予防剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)